Vilazodone HCl
CAS No. 163521-08-2
Vilazodone HCl( EMD 68843 (Hydrochloride) | SB659746A (Hydrochloride) )
Catalog No. M18100 CAS No. 163521-08-2
Vilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 50MG | 53 | In Stock |
|
| 100MG | 77 | In Stock |
|
| 200MG | 113 | In Stock |
|
| 500MG | 184 | In Stock |
|
| 1G | 276 | In Stock |
|
Biological Information
-
Product NameVilazodone HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionVilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.
-
DescriptionVilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.(In Vivo):Administration of 5-HT1A receptor agonists produce a characteristic behavioral syndrome that includes changes in posture, hind limb reduction, head weaving, tremors, forepaw treading, and straub tail. In the rat ultrasonic vocalizations test, stress-induced vocalizations are inhibited by Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (55 mg/kg po) at 120 and 210 min post dose. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (20-40 mg/kg ip), administered acutely or prophylactically (1 week prior to behavioral testing), attenuated stress induces potentiated startle but has no effect on stress potentiated anxiety response in the elevated plus maze. Interestingly, a lower dose of 10 mg/kg of Vilazodone Hydrochloride (EMD 68843 Hydrochloride) has the opposite effect in the startle response, indicating a somewhat unexplained bidirectional effect, and all doses produce a potentiation of the startle-induced stress response possibly suggestive of an anxiogenic-like response. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) also represents another option for the treatment of MDD.
-
In Vitro——
-
In VivoAdministration of 5-HT1A receptor agonists produce a characteristic behavioral syndrome that includes changes in posture, hind limb reduction, head weaving, tremors, forepaw treading, and straub tail. In the rat ultrasonic vocalizations test, stress-induced vocalizations are inhibited by Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (55 mg/kg po) at 120 and 210 min post dose. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (20-40 mg/kg ip), administered acutely or prophylactically (1 week prior to behavioral testing), attenuated stress induces potentiated startle but has no effect on stress potentiated anxiety response in the elevated plus maze. Interestingly, a lower dose of 10 mg/kg of Vilazodone Hydrochloride (EMD 68843 Hydrochloride) has the opposite effect in the startle response, indicating a somewhat unexplained bidirectional effect, and all doses produce a potentiation of the startle-induced stress response possibly suggestive of an anxiogenic-like response. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) also represents another option for the treatment of MDD.
-
SynonymsEMD 68843 (Hydrochloride) | SB659746A (Hydrochloride)
-
PathwayApoptosis
-
TargetIL Receptor
-
Recptor5-HT1A| SSRI
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number163521-08-2
-
Formula Weight477.99
-
Molecular FormulaC26H27N5O2·HCl
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL 52.30 mM;
-
SMILESC1CN(CCN1CCCCc1c[nH]c2c1cc(cc2)C#N)c1cc2c(cc1)oc(c2)C(=O)N.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dawson LA, et al. CNS Neurosci Ther, 2009, 15(2), 107-117.
molnova catalog
related products
-
Aristololactam I
Aristololactam I has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway.
-
Secukinumab
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
-
Spesolimab
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.
Cart
sales@molnova.com